vimarsana.com

Latest Breaking News On - Danielm geynisman - Page 1 : vimarsana.com

ASCO GU 2023: A Phase II Trial of Risk-Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

ASCO GU 2023: A Phase II Trial of Risk-Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

05.09.2022 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology (ESMO) Congress .

GSRGT 2020: Aggressive Surgical Approach for Nodal Disease

GSRGT 2020: Aggressive Surgical Approach for Nodal Disease (UroToday.com) As part of the penile cancer session at the inaugural Global Society of Rare Genitourinary Tumors (GSRGT) 2020 Virtual Summit, Dr. Maarten Albersen from Belgium discussed aggressive surgical approaches for managing patients with nodal disease. Dr. Albersen notes that risk of nodal metastasis is based on the European Association of Urology (EAU) risk delineation: EAU good risk (pT1G1): 0% risk EAU intermediate risk (pT1G2): 9% risk EAU high risk (≥ pT2, G3, or LVI): 23% risk Indeed, appropriate staging of the inguinal lymph nodes is crucial to management. Dynamic sentinel biopsy is one option but has a high false-negative rate outside of high-volume centers. The National Comprehensive Cancer Network (NCCN) guidelines suggest that 20 procedures performed annually should be the baseline, with a steep learning curve of ~30-50 cases. Comparatively, inguinal lymph node dissection has a low false-negative rat

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.